![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 39/395 | (2006.01) |
A61K 45/06 | (2006.01) | ||
A61K 31/337 | (2006.01) | ||
A61K 33/24 | (2019.01) | ||
C07K 16/28 | (2006.01) | ||
A61K 31/513 | (2006.01) | ||
A61K 39/00 | (2006.01) |
(11) | Number of the document | 3027651 |
(13) | Kind of document | T |
(96) | European patent application number | 14752705.5 |
Date of filing the European patent application | 2014-07-31 | |
(97) | Date of publication of the European application | 2016-06-08 |
(45) | Date of publication and mention of the grant of the patent | 2019-02-27 |
(46) | Date of publication of the claims translation | 2019-04-10 |
(86) | Number | PCT/US2014/049008 |
Date | 2014-07-31 |
(87) | Number | WO 2015/017600 |
Date | 2015-02-05 |
(30) | Number | Date | Country code |
201361861198 P | 2013-08-01 | US | |
201361901732 P | 2013-11-08 | US | |
201461933632 P | 2014-01-30 | US |
(72) |
HARDING, Thomas, US
PIERCE, Kristen, US
PATIL, Namrata, US
BRENNAN, Thomas, US
HAMBLETON, Julie, US
|
(73) |
Five Prime Therapeutics, Inc.,
111 Oyster Point Boulevard, South San Francisco, CA 94080,
US
|
(74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
(54) | Afukozilinti anti-FGFR2IIIB antikūnai |
AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIES |
Payment date | Validity (years) | Amount | |
2025-06-19 | 12 | 289.00 EUR |
2026-07-31 |